DUBLIN, Dec. 8, 2023 /PRNewswire/ -- The "Global Premature Ejaculation Therapeutics Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.
The global premature ejaculation therapeutics market was valued at $2,456.71 million in 2023 and is expected to reach $4,062.34 million by 2029, growing at a CAGR of 8.74%. The market growth is mainly attributed to the rising prevalence of premature ejaculation among men globally.
This report offers market size & forecast data for the global premature ejaculation therapeutics market. The revenue generated from the sale of drugs, including off-label products, is included in the report.
The revenue generated from the devices used to manage premature ejaculation, physicians' fees, and other service-related costs is excluded from the report's scope. This report provides a comprehensive and current market scenario of the global premature ejaculation therapeutics market, including the global premature ejaculation therapeutics market size, anticipated market forecast, relevant market segmentations, and industry trends.
The study considers a detailed scenario of the present global premature ejaculation therapeutics market and its market dynamics for 2024?2029. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent players operating in the market.
KEY HIGHLIGHTS
- In 2023, North America and Europe dominated the market with a market share of 43.79% and 25.02%, respectively. APAC is expected to be the fastest-growing market for premature ejaculation (PE) therapeutics in terms of revenue during the forecast period, with a CAGR of 10.56%.
- By drug class, the Selective Serotonin Reuptake Inhibitors (SSRIs) segment was valued at $1,064.41 million in 2023 and is expected to reach $1,759.00 million by 2029, growing at a CAGR of 8.73%. The increased recommendation of SSRIs by healthcare professionals is one of the key factors for the growth of the segment worldwide. SSRIs are considered effective drugs for the treatment of premature ejaculation therapeutics market.
- By Route of Administration, the oral therapeutics segment was valued at $1,847.37 million in 2023 and is expected to reach $2,975.67 million by 2029, growing at a CAGR of 8.27%. The increased recommendation of oral therapeutics by healthcare professionals is one of the key factors for the growth of the segment worldwide. Also, the growing pervasiveness of premature ejaculation and the increasing uptake of generic off-label medications are the key factors enabling the growth of the oral ROA segment.
- By age group, the people aged below 45 years segment was valued at $1,519.11 million in 2023 and is expected to reach $2,536.12 million by 2029, growing at a CAGR of 8.92%. The rise in the prevalence of premature ejaculation in the younger population is the major factor contributing to the market growth during the forecast period.
- Plethora Solutions, Pfizer, Eli Lilly and Company, GSK plc, and the Menarini group are some leading players currently dominating the global premature ejaculation therapeutics market. The major players focus on strategic acquisitions and collaborations with emerging players to enter the premature ejaculation therapeutics market and access commercially launched products.
VENDORS LIST
- Plethora Solutions
- Pfizer
- Absorption Pharmaceuticals
- Eli Lilly and Company
- GSK plc
- Bayer AG
- MidasCare
- Pound International
- Momentum Management
- Reckitt Benckiser Group
- Recordati
- Royalty Pharma
- Shibari
- Johnson & Johnson
- The Menarini Group
- Futura Medical
- Niksan Pharmaceuticals
- Amneal Pharmaceuticals
Key Topics Covered:
1: Pe Therapeutics Market Overview
- Executive Summary
- Key Findings
2: Pe Therapeutics Market
- Global: Projected Revenue of Pe Therapeutics Market (2023-2029; $Millions)
3: Pe Therapeutics Market Segmentation Data
- Global: Projected Revenue by Drug Class (2023-2029; $Millions)
- Ssris
- Pde-5 Inhibitors
- Anesthetic Agents
- Others
- Global: Projected Revenue by Route of Administration (2023-2029; $Millions)
- Oral Therapeutics
- Topical Therapeutics
- Global: Projected Revenue by Age Group (2023-2029; $Millions)
- Below 45 Years
- Above 45 Years
4: Key Regions Overview
- North America: Projected Revenue of Pe Therapeutics Market (2023-2029; $Millions)
- Projected Revenue of Pe Therapeutics Market in US
- Projected Revenue of Pe Therapeutics Market in Canada
- Europe: Projected Revenue of Pe Therapeutics Market (2023-2029; $Millions)
- Projected Revenue of Pe Therapeutics Market in Germany
- Projected Revenue of Pe Therapeutics Market in UK
- Projected Revenue of Pe Therapeutics Market in France
- Projected Revenue of Pe Therapeutics Market in Italy
- Projected Revenue of Pe Therapeutics Market in Spain
- APAC: Projected Revenue of Pe Therapeutics Market (2023-2029; $Millions)
- Projected Revenue of Pe Therapeutics Market in Japan
- Projected Revenue of Pe Therapeutics Market in India
- Projected Revenue of Pe Therapeutics Market in China
- Latin America: Projected Revenue of Pe Therapeutics Market (2023-2029; $Millions)
- Projected Revenue of Pe Therapeutics Market in Brazil
- Projected Revenue of Pe Therapeutics Market in Mexico
- Projected Revenue of Pe Therapeutics Market in Argentina
- Middle East & Africa: Projected Revenue of Pe Therapeutics Market (2023-2029; $Millions)
- Projected Revenue of Pe Therapeutics Market in Turkey
- Projected Revenue of Pe Therapeutics Market in Saudi Arabia
- Projected Revenue of Pe Therapeutics Market in South Africa
5: Pe Therapeutics Market Prospects & Opportunities
- Pe Therapeutics Market Opportunities & Trends
- Pe Therapeutics Market Drivers
- Pe Therapeutics Market Constraints
6: Pe Therapeutics Industry Overview
- Pe Therapeutics Market - Competitive Landscape
- Pe Therapeutics Market - Key Vendor Profiles
- Pe Therapeutics Market - Other Prominent Vendors
- Pe Therapeutics Market - Key Strategic Recommendations
For more information about this report visit https://www.researchandmarkets.com/r/at9gdc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article